Kazunori Nakaoka

12PUBLICATIONS
21CO-AUTHORS
Predictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 28, 2026
Clinical Utility and Genomic Landscape of Comprehensive Genomic Profiling in Biliary Tract Tumors: A Single-Center Real-World Study.

|Jul 15, 2026
Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

|Jan 28, 2026
The Central Role of Liver Function at Treatment Initiation and Its Preservation at Progression for Post-Progression Survival After Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma.

Mizuki Ariga, Teiji Kuzuya, Hisanori Muto

|Dec 30, 2025
Biomarker-Based Responder Selection and Early Prediction of Treatment Response in Hepatocellular Carcinoma: Dynamic Changes in Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin During Atezolizumab Plus Bevacizumab Therapy.

Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi

|Nov 27, 2025
Clinical Outcomes of Reduced-Dose Cabozantinib as Third- or Later-Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real-World Study.

Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi

|Jul 30, 2025
A Case of Extramedullary Plasmacytoma of the Biliary Tract with a Poor Prognosis.

Eiko Sakurai, Kazunori Nakaoka, Seiji Yamada

Pageof 2

Frequent Collaborators

10 joint publications

Yoshiki Hirooka

8 joint publications

Teiji Kuzuya

5 joint publications

Kohei Funasaka

3 joint publications

Senju Hashimoto